iMCD: The spectrum of disease and clinical behaviour - Challenges of long-term management
01:58
Dr. James Cavet, Consultant Haematologist discusses long-term maintenance to reduce the risk of iMCD flares.
Home
THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY
RECOMMENDED DOSING OF SYLVANT®1
- 11 mg/kg given over 1 hour as an intravenous infusion
- Administer every 3 weeks until treatment failure
Use aseptic technique for reconstitution and preparation of dosing solution.1
Once reconstituted, SYLVANT® should not be kept for more than 2 hours prior to the addition to the infusion bag.1
The infusion should be completed within 6 hours of the addition of the reconstituted solution to the infusion bag.1
The patient should have a blood test before each dose of SYLVANT® for the first 12 months and every third
dosing cycle thereafter.1
Consider delaying treatment if the following criteria are not met
(dose reduction is not recommended).
| LABORATORY PARAMETER |
REQUIREMENT BEFORE FIRST SYLVANT® ADMINISTRATION |
RETREATMENT CRITERIA |
|---|---|---|
| Absolute neutrophil count | ≥1.0 x 109/L | ≥1.0 x 109/L |
| Platelet count | ≥75 x 109/L | ≥50 x 109/L |
| Haemoglobin | ‹170 g/L (10.6 mmol/L) | ‹170 g/L (10.6 mmol/L) |
Delay treatment if the patient has a severe infection or any severe non-haematological toxicity – SYLVANT® can be restarted at the same dose after recovery.
Discontinue further SYLVANT® treatment if the patient develops:1
- Severe infusion related reaction
- Anaphylaxis
- Severe allergic reaction
- Cytokine release syndrome related to the infusion
Consider discontinuing SYLVANT® if there are more than 2 dose delays due to toxicities related to the treatment during the first 48 weeks.
Special populations – please refer to the full EU SmPC1 for further details.
References
1. SYLVANT® EU Summary of Product Characteristics (2019).
© 2021 EUSA Pharma
Date of prep: November 2021 GL-SIL-2100106
This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.
© 2021 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ